Health Canada grants market authorisation for Kalydeco (ivacaftor) in children ages 12 to <24 months with certain mutations in the CFTR gene

28 January 2019 - Kalydeco is the first and only approved medicine in Canada to treat the underlying cause of ...

Read more →

Ipsen announces FDA approval of Dysport (abobotulinumtoxinA) for injection for the treatment of lower limb spasticity in children aged two and older

1 August 2016 - First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity. ...

Read more →

CADTH calls for patient input on a new submission from Novartis for Ilaris

24 November 2015 - CADTH has received notice of a pending submission from Novartis for canakinumab (Ilaris) for use by patients ...

Read more →

CMS announces $32 million to help get eligible children enrolled in health coverage

16 November 2015 - The Centers for Medicare & Medicaid Services today announced $32 million in available funds to support efforts ...

Read more →

NICE not in favour of drug for neuroblastoma

5 November 2015 - It looks like children and adolescents with neuroblastoma will not be able to access United Therapeutics’ Unituxin ...

Read more →

NICE draft guidance recommends treatments for arthritis in children

21 October 2015 - Health care guidance body NICE has today published final draft guidance recommending 4 drugs for treating a ...

Read more →